文献速递头痛与眩晕

丛集性头痛诊断、管理与病理生理学认识的最新进展

Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache.
PubMed 文献 · Lancet Neurol · 2024-01-01

丛集性头痛以严重复发性单侧头痛及同侧颅自主神经症状为特征,病理生理机制尚不明确。近期研究识别出八个相关基因位点,神经刺激靶向三叉自主反射或靶向降钙素基因相关肽(CGRP)可能减轻发作负担。美国食品药品监督管理局已批准靶向CGRP的单克隆抗体galcanezumab作为发作性丛集性头痛的首个特异性预防治疗,但慢性丛集性头痛未重复出预防效果,欧洲药品管理局未批准该药。

要点

  • 丛集性头痛全球患者临床特征相似,但患病率和负担存在地区差异。
  • 国际协作已识别出八个与丛集性头痛相关的基因位点。
  • galcanezumab获美国食品药品监督管理局批准用于发作性丛集性头痛预防,但慢性丛集性头痛未重复出预防效果。

核心结论

  • 靶向三叉自主反射的神经刺激或靶向CGRP可能减轻丛集性头痛发作负担。
  • galcanezumab是美国食品药品监督管理局批准的首个发作性丛集性头痛特异性预防治疗,但慢性丛集性头痛未重复出预防效果。
  • 由于丛集性头痛患病率低,持续通过多中心临床试验和数据共享开展协作对进一步突破至关重要。

研究设计与样本

  • 综述总结了丛集性头痛诊断、管理和病理生理学认识的最新进展。

主要发现

  • 丛集性头痛患者临床特征全球相似,但患病率和负担存在地区差异。
  • 国际协作已识别出八个与丛集性头痛相关的基因位点。
  • 靶向三叉自主反射的神经刺激或靶向CGRP可能减轻发作负担。
  • 美国食品药品监督管理局已批准galcanezumab作为发作性丛集性头痛的首个特异性预防治疗。
  • 慢性丛集性头痛未重复出galcanezumab的预防效果,欧洲药品管理局未批准该药,限制其在欧洲的可及性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 丛集性头痛的病理生理机制仍未完全明确。
  • 由于丛集性头痛患病率低,需通过多中心临床试验和数据共享持续协作以取得进一步突破。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cluster headache, characterised by attacks of severe, recurrent, unilateral headache and ipsilateral cranial autonomic symptoms, remains a primary headache with an elusive pathophysiology. Recent advances have introduced effective treatments and broadened understanding of the clinical features of cluster headache. These features are similar in patients globally, but regional differences in prevalence and burden exist. International collaborations have led to identification of eight genetic loci associated with cluster headache. The pathophysiological mechanisms are still not fully understood but recent studies show that targeting the trigeminal autonomic reflex by neurostimulation, or targeting the neuropeptide calcitonin gene-related peptide (CGRP), might lessen the attack burden. The US Food and Drug Administration has approved galcanezumab, a monoclonal antibody targeting CGRP, as the first specific preventive treatment for episodic cluster headache. However, a preventive effect was not replicated in chronic cluster headache, and the European Medicines Agency did not approve galcanezumab, restricting its availability in Europe. Owing to the low prevalence of cluster headache, continued collaboration through multicentre clinical trials and data sharing will be imperative for further breakthroughs in understanding and management.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Petersen AS, Lund N, Goadsby PJ, et al. Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache. Lancet Neurol. 2024. PMID: 38876749. doi:10.1016/S1474-4422(24)00143-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。